title: Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.
abstract: BACKGROUND
  Peritoneal carcinomatosis has been regarded as a lethal clinical entity. Recently, aggressive treatments combining intraperitoneal chemohyperthermia (IPCH) with cytoreductive surgery have resulted in long-term survival in selected patients. The aim of this trial was to analyze the mortality and morbidity of 216 consecutive treatments of peritoneal carcinomatosis by IPCH by using a closed abdominal procedure combined with cytoreductive surgery.
  
  
  METHODS
  Between February 1989 and August 2001, 207 patients who underwent 216 IPCH procedures using a closed abdominal procedure with mitomycin C, cisplatin, or both were prospectively studied.
  
  
  RESULTS
  The postoperative mortality and morbidity rates were 3.2% and 24.5%, respectively. The most frequent complications were digestive fistula (6.5%) and hematological toxicity (4.6%). Morbidity was statistically linked with the carcinomatosis stage (P =.016), the duration of surgery (P =.005), and the number of resections and peritonectomy procedures (P =.042). Duration of surgery and carcinomatosis stage were the most common predictors of morbidity.
  
  
  CONCLUSIONS
  The frequency of complications after IPCH and cytoreductive surgery was mainly associated with the carcinomatosis stage and the extent of the surgical procedure. The IPCH closed abdominal procedure has shown an acceptable frequency of adverse events.
authors.affiliation: Department of Surgery, Centre Hospitalier Lyon-Sud, Pierre Bénite Cédex, France.
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.forename: D
authors.initials: D
authors.lastname: Osinsky
authors.forename: E
authors.initials: E
authors.lastname: Cotte
authors.forename: F
authors.initials: F
authors.lastname: Kwiatkowski
authors.forename: G
authors.initials: G
authors.lastname: Freyer
authors.forename: S
authors.initials: S
authors.lastname: Isaac
authors.forename: V
authors.initials: V
authors.lastname: Trillet-Lenoir
authors.forename: A C
authors.initials: AC
authors.lastname: Sayag-Beaujard
authors.forename: Y
authors.initials: Y
authors.lastname: François
authors.forename: J
authors.initials: J
authors.lastname: Vignal
authors.forename: F N
authors.initials: FN
authors.lastname: Gilly
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D011183:Postoperative Complications; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D002945:Cisplatin